OLEMA PHARMACEUTICALS, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $1.05 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-28.
Discontinued › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2022-02-28
- OLEMA PHARMACEUTICALS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-12-31 was $0.00.
- OLEMA PHARMACEUTICALS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-09-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-06-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-03-31 was $1.05M.
- OLEMA PHARMACEUTICALS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2020 was $1.05M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $1.05M 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $1.05M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $1.05M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $1.05M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |